Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Vanda Pharmaceuticals, Inc.
28 6월 2013 - 10:07AM
Business Wire
Glancy Binkow & Goldberg LLP announces that a class action
lawsuit has been filed in the United States District Court for the
District of Columbia on behalf of a class (the “Class”) comprising
all purchasers of the securities of Vanda Pharmaceuticals, Inc.
(“Vanda” or the “Company”) (NASDAQ:VNDA) between December 18, 2012
and June 18, 2013, inclusive (the “Class Period”).
A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM
GLANCY BINKOW & GOLDBERG LLP. PLEASE CONTACT US TOLL-FREE AT
(888) 773-9224, OR AT (212) 682-5340, OR BY EMAIL TO
SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER. IF YOU INQUIRE
BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND
NUMBER OF SHARES PURCHASED.
Vanda is a biopharmaceutical company engaged in the development
and commercialization of products for the treatment of central
nervous system disorders, including tasimelteon -- a treatment for
circadian rhythm sleep disorders (CRSD) and currently in clinical
development for a serious, rare CRSD known as “Non-24.” The
Complaint alleges that during the Class Period the Company issued
false and/or misleading statements and/or failed to disclose that:
(a) the Company was forced to unilaterally change the primary
endpoint in the middle of the tasimelteon Phase III studies as it
was in possession of data suggesting the original primary endpoint
would not be met; (b) the Company eliminated nighttime total sleep
as the primary endpoint in its studies as there was no discernible
difference in efficacy and safety in nighttime total sleep between
those patients deemed to have Non-24 and those patients with a
normal circadian rhythm; (c) the replacement primary endpoint
installed to assess tasimelteon’s efficacy and safety was created
by the Company based on predicted results and has never been used
before in sleep-drug clinical trials, nor was it endorsed by the
Food and Drug Administration; and (d) as a result of the foregoing,
the Company’s statements were materially false and misleading at
all relevant times.
If you are a member of the Class described above you may move
the Court no later than 60 days from June 25, 2013 to serve as lead
plaintiff; however, you must meet certain legal requirements.
If you wish to learn more about this action or if you purchased
Vanda securities prior to the Class Period and have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Michael Goldberg, Esquire,
of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite
2100, Los Angeles, California 90067, Toll Free at (888) 773-9224,
or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg
LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at
(212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit
our website at http://www.glancylaw.com. If you inquire by email
please include your mailing address, telephone number and number of
shares purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP, Los Angeles, CAMichael
Goldberg(888) 773-9224orGlancy Binkow & Goldberg LLP, New York,
NYGregory Linkh(212) 682-5340 or (888)
773-9224shareholders@glancylaw.comwww.glancylaw.com
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024